Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE1

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-13

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase 1, first-in-human (FIH), open-label, multicenter, study of LB1901 administered to adult subjects with histologically confirmed CD4+ relapsed or refractory Peripheral T-cell lymphoma (PTCL) (PTCL not otherwise specified \[PTCL-NOS\] and angioimmunoblastic \[AITL\]), or relapsed or refractory cutaneous T-cell lymphoma (CTCL) (Sézary syndrome \[SS\] and mycosis fungoides \[MF\]).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19

NCT01864889

Hematopoietic/Lymphoid Cancer Adult Acute Lymphoblastic Leukemia in Remission B-cell Adult Acute Lymphoblastic Leukemia +20 more

UNKNOWN NA

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22

NCT03185494

Hematopoietic/Lymphoid Cancer Adult Acute Lymphoblastic Leukemia in Remission B-cell Adult Acute Lymphoblastic Leukemia +20 more

UNKNOWN PHASE1/PHASE2

Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma

NCT06830031

Diffuse Large B-cell-lymphoma DLBCL, Nos Genetic Subtypes Follicular Lymphoma Grade 3B +3 more

RECRUITING PHASE1

LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor

NCT04973527

T Cell Lymphoma T-cell Leukemia

TERMINATED PHASE1

CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies

NCT04162340

T Cell Lymphoma in Relapse Refractory T-Cell Lymphoma

UNKNOWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study Design: This is a Phase 1, first-in-human (FIH), open-label, multicenter, multicohort study of LB1901 administered to adult subjects with histologically confirmed CD4+ relapsed or refractory Peripheral T-cell lymphoma (PTCL) (PTCL not otherwise specified \[PTCL-NOS\] and angioimmunoblastic \[AITL\]), or relapsed or refractory cutaneous T-cell lymphoma (CTCL) (Sézary syndrome \[SS\] and mycosis fungoides \[MF\]).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

T-Cell Lymphoma Peripheral T-Cell Lymphoma Refractory Cutaneous T-Cell Lymphoma Refractory Cutaneous T-Cell Lymphoma Recurrent Peripheral T-Cell Lymphoma Recurrent

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental LB1901

Drug: anti-CD4 CAR T cells anti-CD4 CAR T cells transduced with a lentiviral vector to express CD4 chimeric receptor domain on T cells.

Group Type EXPERIMENTAL

LB1901

Intervention Type BIOLOGICAL

LB1901 - an autologous CD4-targeted CAR-T immunotherapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LB1901

LB1901 - an autologous CD4-targeted CAR-T immunotherapy

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Written informed consent.
2. Subjects ≥ 18 years of age.
3. Histologically confirmed diagnosis of CD4+ PTCL-NOS; OR CD4+ AITL; OR CD4+ CTCL(either MF or SS).
4. Relapsed or refractory disease with at least two prior lines of systemic antineoplastic therapy.

* Subjects with confirmed CD30+ PTCL or MF must have previously received brentuximab vedotin.
* Subjects should have received at least two prior lines of standard of care therapies.
5. For Subjects with PTCL-NOS or AITL, at least one measurable lesion according to the International Working Group (IWG) Response Criteria.
6. For subjects with CTCL, disease stage IIB or higher based on TNMB system.
7. Subjects must have an identified hematopoietic stem cell transplant (HSCT) donor available prior to enrollment. HLA typing may be performed for source identification.
8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
9. Adequate organ function.
10. Women of childbearing potential must have a negative pregnancy test at screening.
11. All Subject must agree to practice a highly effective method of contraception.
12. Women and men must agree not to donate eggs (ova, oocytes) or sperm, respectively, until at least 1 year after receiving a LB1901.

Exclusion Criteria

1. Histologically confirmed CD8+ TCL - CD8 positivity in tumor must be confirmed within 3 months prior to apheresis by IHC or flow cytometry.
2. Prior treatment with cellular immunotherapy (e.g., CAR-T) or gene therapy product directed at any target.
3. Prior treatment with CD4-targeted therapy.
4. History of allogeneic haematopoietic stem cells transplant.
5. Antitumor therapy prior to apheresis as follows:

* Any systemic anticancer therapy (chemotherapy, targeted therapy including ADC, epigenetic therapy including HDAC inhibitor, retinoids, pralatrexate, proteasome inhibitor therapy, investigational drug) within 21 days or at least 5 half-lives, whichever is shorter.
* Anti-CCR4 monoclonal antibody or any other monoclonal antibody within 4 weeks or at least 5 half-lives, whichever is shorter.
* Cytotoxic therapy within 14 days.
* Immunomodulatory agent therapy within 7 days.
* Radiotherapy within 14 days.
6. Immunosuppressant (e.g., cyclosporine or systemic steroids) above physiologic dosing within 7 days of apheresis.
7. Therapeutic anticoagulants (such as warfarin, heparin, low molecular weight heparin) (at least 3 half-lives must have elapsed after the last dose at the time of apheresis).
8. CNS disease prophylaxis (e.g., intrathecal methotrexate) at least 7 days before apheresis.
9. History or active Hepatitis B or C infection (except hepatitis C cured with pharmacotherapy); or history of or current HIV infection.
10. History of autoimmune disease requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years.
11. Primary immunodeficiency.
12. Active CNS disease related to the underlying malignancy.
13. Stroke or seizure within 6 months of apheresis.
14. Impaired cardiac function or clinically significant cardiac disease.
15. Previous or concurrent malignancy with the following exceptions:

* Adequately treated basal cell or squamous cell carcinoma.
* In situ carcinoma of the cervix or breast, treated curatively and without evidence of recurrence for at least 3 years prior to screening.
* A primary malignancy which has been completely resected, or treated, and is in complete remission for at least 3 years prior to screening.
16. Serious and/or uncontrolled medical condition that, in the Investigator's judgment, would cause unacceptable safety risk.
17. Ongoing toxicity from previous anticancer therapy that has not resolved to baseline levels or to Grade 1 or less, except for alopecia, fatigue, nausea, and constipation.
18. Major surgery within 4 weeks prior to apheresis, or planned within 4 weeks after LB1901 administration.
19. Contraindications or life-threatening allergies, hypersensitivity, or intolerance to LB1901 or its excipients, including dimethyl sulfoxide; or to fludarabine, cyclophosphamide, or tocilizumab.
20. Contraindication or life-threatening allergy to valacyclovir, unless another suitable option of antiviral prophylaxis is identified after consultation with an Infectious Disease specialist.
21. Pregnant or breast-feeding.
22. Plans to become pregnant or breastfeed, or father a child within 1 year after receiving a LB1901 infusion.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No